The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2015
Filed:
Sep. 19, 2012
Stc.unm, Albuquerque, NM (US);
University of Kansas, Lawrence, KS (US);
Richard Smith Larson, Albuquerque, NM (US);
Larry A. Sklar, Albuquerque, NM (US);
Bruce S. Edwards, Albuquerque, NM (US);
Juan Jacob Strouse, Albuquerque, NM (US);
Irena Ivnitski-Steele, Coral Springs, FL (US);
Hadya M. Khawaja, Albuquerque, NM (US);
Jerec Warren Ricci, Albuquerque, NM (US);
Jeffrey Aube, Lawrence, KS (US);
Jennifer Elizabeth Golden, Olathe, KS (US);
Tuanli Yao, Lawrence, KS (US);
Warren S. Weiner, Lawrence, KS (US);
Chad E. Schroeder, Lawrence, KS (US);
STC.UNM, Albuquerque, NM (US);
UNIVERSITY OF KANSAS, Lawrence, KS (US);
Abstract
The present invention provides pyrazolo[1,5-a]pyrimidine compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1. Compounds and compositions according to the present invention may be used to treat cancer, including drug resistant (DR) and multiple drug resistant (MDR) cancers.